Schwaiblmair Martin, Behr Werner, Haeckel Thomas, Märkl Bruno, Foerg Wolfgang, Berghaus Thomas
Department of Internal Medicine I, Klinikum Augsburg, Ludwig-Maximilians-University of Munich, Germany.
Open Respir Med J. 2012;6:63-74. doi: 10.2174/1874306401206010063. Epub 2012 Jul 27.
With an increasing number of therapeutic drugs, the list of drugs that is responsible for severe pulmonary disease also grows. Many drugs have been associated with pulmonary complications of various types, including interstitial inflammation and fibrosis, bronchospasm, pulmonary edema, and pleural effusions. Drug-induced interstitial lung disease (DILD) can be caused by chemotherapeutic agents, antibiotics, antiarrhythmic drugs, and immunosuppressive agents. There are no distinct physiologic, radiographic or pathologic patterns of DILD, and the diagnosis is usually made when a patient with interstitial lung disease (ILD) is exposed to a medication known to result in lung disease. Other causes of ILD must be excluded. Treatment is avoidance of further exposure and systemic corticosteroids in patients with progressive or disabling disease.
随着治疗药物数量的增加，导致严重肺部疾病的药物清单也在增长。许多药物都与各种类型的肺部并发症有关，包括间质性炎症和纤维化、支气管痉挛、肺水肿和胸腔积液。药物性间质性肺病（DILD）可由化疗药物、抗生素、抗心律失常药物和免疫抑制剂引起。DILD没有明显的生理、影像学或病理模式，通常在间质性肺病（ILD）患者接触已知会导致肺部疾病的药物时做出诊断。必须排除ILD的其他病因。对于病情进展或致残的患者，治疗方法是避免进一步接触药物并使用全身性皮质类固醇。
